Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.

MLA

Krauss, Daniel J., et al. “Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 17, June 2023, pp. 3203–16. EBSCOhost, https://doi.org/10.1200/JCO.22.02390.

APA

Krauss, D. J., Karrison, T., Martinez, A. A., Morton, G., Yan, D., Bruner, D. W., Movsas, B., Elshaikh, M., Citrin, D., Hershatter, B., Michalski, J. M., Efstathiou, J. A., Currey, A., Kavadi, V. S., Cury, F. L., Lock, M., Raben, A., Seaward, S. A., El-Gayed, A., … Sandler, H. M. (2023). Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 41(17), 3203–3216. https://doi.org/10.1200/JCO.22.02390

Chicago

Krauss, Daniel J, Theodore Karrison, Alvaro A Martinez, Gerard Morton, Di Yan, Deborah Watkins Bruner, Benjamin Movsas, et al. 2023. “Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41 (17): 3203–16. doi:10.1200/JCO.22.02390.